[{"from": "human", "value": "What can you tell me about this molecule? [C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][=N][C][=C][Branch1][O][C][=Branch1][C][=O][N][C][=C][Ring1][#Branch1][Br][C][=Branch1][Ring2][=N][Ring1][N][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1].[Cl]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, FLT3 inhibitor SKI-G-801 binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, SKI-G-801 also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C."}]